This paper discusses the changes of CD41, CD62P, ET-1, t-PA, PAI-1, FIB, APTT, PT, and TT in asthma patients with abnormal Savda. Totally 76 asthmatic patients were syndrome typed according to the body fluid theory of Uygur medicine. Among them, there were 30 asthmatic patients with abnormal Savda and 46 asthmatic patients without abnormal Savda. A comparison study was performed with 89 normal individuals (as the healthy control group). The expression of CD62P on platelets, the level of plasma tissue plasminogen activator (t-PA) and its inhibiter (PAI-1), the level of endothelin-1 (ET-1), activated partial thromboplastin time (APTT), fibrinogen (FIB), prothrombin time (PT) and thrombin time (TT) were tested by using flow cytometer, ELASA method, radioimmunoassay method and auto coagulometer. Finally, we found the followings. Compared to the normal control group, there was no significance between the expressions of the asthma with abnormal Savda group and the asthma without abnormal Savda group (P> 0.05); For the expression of CD62P in all the three groups (P<0.05), the expression of CD62P in the asthma with abnormal Savda group was significantly higher than that of the asthma without abnormal Savda group (P<0.05); The level of serum ET-1 was significantly higher in both the asthma with abnormal Savda and the asthma without abnormal Savda groups (P<0.05); The level of ET-1 was significantly higher in the asthma with abnormal Savda group than those of the asthma without abnormal Savda group and the normal control group (P<0.01); The level of plasma t-PA was significantly lower in both the asthma with abnormal Savda and the asthma without abnormal Savda groups (P<0.05); The level of serum PAI-1 was significantly higher in both the asthma with abnormal Savda and the asthma without abnormal Savda groups (P<0.05); The level of plasma FIB was significantly higher in the asthma with abnormal Savda and asthma without abnormal Savda groups (P<0.05), the level of plasma FIB was significantly higher in the asthma with abnormal Savda group than those of the asthma without abnormal Savda group and the normal control group; The level of APTT and PT were significantly shortened in the asthma with abnormal Savda and asthma without abnormal Savda groups (P<0.05). There was no significance on TT between these three groups.
[1] Bauer K A, Rosenberg R D. The pathophysiology of the perthrombotic state in humans: Insights gained from stadies using markers of hemostatic system activation[J]. Blood, 1987, 70(2): 343-350.
[2] 常玉荣, 杨德全, 唐福美, 等. 血栓栓塞性疾病血栓前状态的实验室诊断[J]. 中国综合临床, 2001, 17(2): 83. Chang Yurong, Yang Dequan, Tang Fumei. Thromboembolic disease before thrombus state laboratory diagnosis[J]. Clinical Medicine of China, 2001, 17(2): 83.
[3] Beather E, LichtmanM A, Coller B S, et al. Hematollgy[M]. 6th ed. New York: McGraw Hill, 2001: 1735-1763.
[4] 宗俊学, 芦璐, 徐洪玉. 血栓前状态与高血压病的关系[J]. 血栓与止血学, 2005, 11(1): 21-23. Zong Junxue, Lu Lu, Xu Hongyu. The relationship between prethromboticseate and hypertension[J]. Chinese Journal of Thrombosis and Hemostasis, 2005, 11(1): 21-23.
[5] Falanga A, Tickles F R. Pathophysiology of the thrombophilic state in the cancer patient[J]. Seminars in Thromband Hemostasis, 2002, 25(2): 173-182.
[6] Sarkar R R, Banerjee S. Cancer self remission and tumor stability a stochastic approach[J]. Mathematical Biosciences and Engineering, 2005,196(1): 65-81.
[7] CalveteJ J. Clues for understanding the structure and function of a prototypic human integrin: The platelet glycoproteinIIb/III acomplex[J]. Thrombosis andHaemostasis, 1994, 7(1): 11-16.
[8] Egidy G, Juillerat J L, Jeannin J F, et al. Modulation of human colon tumor-stromalinter actions by the endothelin system[J]. American Journalof Pathology, 2000, 157(6): 1863-1874.
[9] Calvete J J. Clues for understanding the structure and function of a prototypic human integrin: The platelet glycoproteinIIb/III acomplex[J]. Thrombosis and Haemostasis, 1994, 7(1): 11-16.
[10] Erlandsen S L, Bittermann A G, White J, et al. High-resolutioncryofesemof individual cell adhesion molecules (CAMs) in theglycocalyx of human platelets: Detection of P-selectin(CD62P), GPI-IX complex (CD42a/CD42b, bß), and integrin GPIIb/IIIa(CD41/CD61) byimmunogold labeling and stereo imaging[J]. Journal of Histochemistry and Cytochemistry, 2001, 49(7): 809-819.
[11] Suzuki S, Hayashi Y, Wang Y, et al. Urokinase type pkasminogen activator receptor expression in colorectal neoplasms[J]. Gut, 1998, 43(6): 798-805.
[12] 哈木拉提·吾甫尔. 维吾尔医学气质、体液论及其现代研究[M]. 乌鲁木齐: 新疆科学技术出版社, 2003, 7: 75-77. Upur Halmurat. Theory of mizaj and hilit in Uighur medicine and mordern study[M]. Urumqi: Xinjiang Science and Technology Publishing House, 2003, 7: 75-77.
[13] 中华医学会呼吸病学分会哮喘学组. 支气管哮喘防治指南(支气管哮喘的定义、诊断、治疗及教育和管理方案)[J]. 中华结核和呼吸杂志, 2003, 26(3): 132-136. Bronchial Asthmatic Group of Respiratory Medicine Branch of Chinese Association. The Chinese medical association respiratory epidemiology (Bronchial asthmatic diagnosis and treatment guidelines) [J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2003, 26(3): 132-136.
[14] 巴克·阿里木阿吉. 维吾尔医诊断学[M]. 乌鲁木齐: 新疆人民卫生出版社, 2012: 111-120. Alemajim Bak. Uighur medical diagnostics[M]. Urumqi: Xinjiang People's Medical Publishing House, 2012: 111-120.
[15] 哈木拉提·吾甫尔. 维吾尔医气质、体液论及其现代研究[M]. 乌鲁木齐: 新疆科学技术出版社, 2003: 40-47. Upur Halmurat. Theory of mizaj and hilit in uighur medicine and mordern study[M]. Urumqi: Xinjiang Science and Technology Publishing House, 2003: 40-47.
[16] Dunn E J, Grant P J. Type 2 diabes: Anatherothrombotic syndrome[J]. Current Molecular Medicine, 2005, 5(3): 323-332.
[17] Lip G Y, Edmunds E, Beevers D G. Should patients with hyper-tension receive antithrombotic therapy?[J]. Journal of Internal Medicine, 2001, 249(3): 205-214.
[18] 严宗毅, 魏茂元, 于天文. 血液流变学[M]. 哈尔滨: 黑龙江科学技术出版社, 1993: 209-215. Yan Zongyi, Wei Maoyuan, Yu Tianwen. Hemorheology[M]. Harbin: Heilongjiang Science and Technology Publishing House, 1993: 209-215.
[19] Korbut R, Gryglewski R J. The effect of prostacyclin and nitric oxide on deformability of red blood cells in septic shock in rats[J]. Physiology and Pharmacology, 1996, 47(4): 591-599.
[20] Baskurt O K, Gdmont D, Meiselman H J. Red blood cell deformability in sepsis[J]. American Journal of Respiratory and Critical Care Medicine, 1998, 157: 421-427.
[21] 武焕玲, 林隆玖. 血栓前状态研究进展[J]. 中国实验诊断学, 2003, 7 (4): 277-280. Wu Huanling, Lin Longjiu. The reviewed of prethromboticseate[J]. Chinese Journal of Laboratory Diagnosis, 2003, 7(4): 277-280.
[22] 李家增. 血管血栓性疾病的发病机制和防治[J]. 基础医学与临床,2006, 26(6): 561-565. Li Jiazeng. Pathogenic mechanism and treatment of vascular thromboenbolismdisease[J]. Basic Medical Sciences and Clinics, 2006, 26 (6): 561-565.
[23] Ferguson J J, Waly H M, Wilson J M. Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition[J]. European Heart Journal, 1998, 19(S1): D3.
[24] 徐宜, 孙文学. 老年糖尿病肾病血小板活化分子检测的意义[J]. 黑龙江医学, 2004, 28(1): 26-28. Xu Yi, Sun Wenxue. Significance of detection of platelet activation markers in elderly diabetic nephropathy[J]. Heilongjiang Medical Journal, 2004, 28(1): 26-28.
[25] Zizzi H C, Zibari G B, Granger D N, et al. Quantification of P-selectin expression after renal ischemia and reperfusion[J]. Journal of Pediatric Surgery, 1997, 32(7): 1010-1013.
[26] Miamino T, Kitakase M, Sanada S, et al. Increased expression of P-selection on platelets is a risk factor for silent cerebalinfaction in patients with atrial fibrillation[J]. Circulation, 1998, 98(3): 1721-1727.
[27] Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells[J]. Nature, 1988, 332(6163): 411-415.
[28] 陶连方. 老年高血压病糖尿病患者血浆内皮素测定及其意义[J]. 中国微循环, 2003, 7(4): 245. Tao Lianfang. Significance of detection of plasma endothelium in elderly diabetic nephropathy and hypertension[J]. Journal of Chinese Microcirculation, 2003, 7(4): 245.
[29] Nguyen-Ho P, Lakkis N M. Platelet glycoprotein IIb/IIIa a receptor antagonists and coronary disease[J]. Current Atherosclerosis Reports, 2001, 3(2): 139-148.
[30] 王振义, 李家增, 阮长耿, 等. 纤维蛋白溶解系统[C]//上海第二医科大学编辑委员会. 血栓与止血基础理论与临床. 2版. 上海: 上海科学技术出版社, 1996. Wang Zhenyi, Li Jiazeng, Ruan Changgeng, et al. Fibrinolytic system[C]//Editorial Committee of Shanghai Second Medical University. The Basic Theory and Clinical of Thrombosis and Haemostasis. 2nd ed. Shanghai: Shanghai Science and Technology Publishing House, 1996.
[31] 丛玉隆, 王淑娟, 朱士俊, 等. 纤溶系统的组成及特点[C]//今日临床检验学编辑委员会编. 今日临床检验学. 北京: 中国科学技术出版社, 1997. Cong Yulong, Wang Shujuan, Zhu Shijun, et al. The composition and the characteristics of fibrinolytic system[C]//Today Clinical Inspection Editorial Board. Today Clinical Test. Beijing: China Science and Technology Publishing House, 1997.
[32] Bernd R B, Gunter C, Florian G, et al. Plasminogen activator inhibitor physiological and pathophysiological roles[J]. Newsin Physiological Sciences, 2002, 17: 56-61.
[33] 葛郁芝, 刘冬生. 高血压病患者血栓前状态P-选择素等标志物变化及其临床意义[J]. 中国心血管病研究杂志, 2005, 3(12): 896-899. Ge Yuzhi, Liu Dongsheng. Levels of P selection and its clinic significance in hypertensive patients with prothromboticstatus[J]. Chinese Journal of Cardiovascular Review, 2005, 3(12): 896-899.
[34] Qizilbash N, Duffy S, Prentice C R M, et al. Willebrand factor and risk of ischemic stroke[J]. Neurology, 2001, 53(6): 1552-1556.
[35] Yamell J W G, Baker I A. Sweetnam P M, et al. Fibrinogen, viscosity and white blood cell count are major risk factor for ischemic heart disease[J]. Circulation, 1991, 83: 836.
[36] 居来提·托乎提, 阿不都克热木江·吐尔逊托乎提. 维吾尔医学对哮喘病因的认识[J]. 中国民族医学杂志, 2004, 10(4): 3-4. Tuohuti Julaiti, Tuerxuntuohuti Abudukeremujian. Recognize on the Uygur traditional medicine for asthma cause[J]. Journal of Medicine & Pharmacy of Chinese Minorities, 2004, 10(4): 3-4.
